Evidence map›Paper›PMID 39381188›Full record

ArticleJAACAP open2023

Examining Factors Associated With Medication Adherence in Youth With Bipolar Disorder.

Mohamed Y Elhosary, John A Merranko, Tina R Goldstein, Danella M Hafeman, Benjamin I Goldstein, Mary Kay Gill, Heather Hower, David A Axelson, Jeffrey I Hunt, Shirley Yen and 6 more

Abstract read
In one paragraph

Article in JAACAP open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mohamed Y ElhosaryUPMC Western Psychiatric Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania.
John A MerrankoUPMC Western Psychiatric Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania.
Tina R GoldsteinUPMC Western Psychiatric Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania.
Danella M HafemanUPMC Western Psychiatric Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania.
Benjamin I GoldsteinCentre for Youth Bipolar Disorder, Centre for Addiction and Mental Health, University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.
Mary Kay GillUPMC Western Psychiatric Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania.
Heather HowerWarren Alpert Medical School of Brown University, Providence, Rhode Island.
David A AxelsonNationwide Children's Hospital, and The Ohio State College of Medicine, Columbus, Ohio.
Jeffrey I HuntWarren Alpert Medical School of Brown University, Providence, Rhode Island.
Shirley YenWarren Alpert Medical School of Brown University, Providence, Rhode Island.
Rasim Somer DilerUPMC Western Psychiatric Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania.
Neal D RyanUPMC Western Psychiatric Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania.
Martin B KellerWarren Alpert Medical School of Brown University, Providence, Rhode Island.
Lauren M WeinstockWarren Alpert Medical School of Brown University, Providence, Rhode Island.
Michael StroberDavid Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Boris BirmaherUPMC Western Psychiatric Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania.

Funding

Course and Outcome of Bipolar Disorder in Youth - SupplementR01MH059929 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BIRMAHER, BORIS, PHILLIPS, MARY LOUISE · 2000 to 2021
$15.9M
Course and Outcome for Bipolar Disorder in Youth (COBY)R01MH059691 · NIMH · BROWN UNIVERSITY · PI KELLER, MARTIN B, YEN, SHIRLEY · 2000 to 2015
$7.9M
Course and Outcome for Bipolar Disorder in YouthR01MH059977 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI STROBER, MICHAEL A · 2000 to 2010
$3.7M
1/2 Predicting Adult Outcomes in Bipolar Youth (PROBY)R01MH112544 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BIRMAHER, BORIS · 2018 to 2022
$2.5M
2/2-Predicting Adult Outcomes in Bipolar Youth (PROBY)R01MH112543 · NIMH · BROWN UNIVERSITY · PI YEN, SHIRLEY · 2018 to 2022
$1.2M
NIMH NIH HHS R01 MH059691NIMH NIH HHS R01 MH059929NIMH NIH HHS R01 MH059977NIMH NIH HHS R01 MH112543NIMH NIH HHS R01 MH112544
6 · The paper itself

Abstract

Objective: To assess medication adherence and factors associated with poor adherence in youth with bipolar disorder (BD) followed from adolescence through young adulthood. Method: Participants with BD recruited through the Course and Outcome of Bipolar Youth (COBY) study were included in this study if they were prescribed psychotropic medications and had at least 3 follow-up assessments of medication adherence (N= 179, ages 12-36). Medication adherence had been evaluated for a median of 8 years using a questionnaire derived from the Coronary Artery Risk Development in Young Adults (CARDIA) study. For the longitudinal evaluation, adherence was measured as the percentage of follow-up assessments in which the participants did not endorse any of the nonadherence items included in the questionnaire. Concurrent and future predictors of poor adherence were assessed using both univariate and multivariate longitudinal analyses. Results: Among the participants, 51% reported poor adherence in more than 50% of their follow-up assessments. Younger age, family conflicts, polypharmacy, lower functioning, greater severity of mood symptoms, and comorbid disorders were associated with poor adherence in the univariate analyses. In the multivariate analyses, comorbid ADHD was the single most influential factor associated with concurrent and future poor adherence in all age groups. Participants' most reported reasons for poor adherence were forgetfulness (56%), negative attitudes toward medication treatment (10.5%), and disturbed daily routine (7%). Conclusions: Poor medication adherence is a significant problem in youth with BD with the most influential factor being the presence of comorbid ADHD. Thus, it is important to identify and appropriately treat comorbid ADHD to improve medication adherence and patients' prognosis. Providers should also recommend tools to enhance consistent medication intake and address patients' concerns and negative beliefs about their illness and treatment.

Identifiers

PMID39381188
PMCPMC11460791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.